Antipsychotic drugs are known to be antagonists of the dopamine D 2 receptor and this is generally considered to be their mode of action. More recently the dopamine D 2 receptor has been found to consist of a family of receptors composed of the D 2 , D 3 , and D 4 receptors. 9 The D 2 receptor subtype is located in the caudate, putamen, nucleus accumbens, globus pallidus and lesser amounts in the substantia nigra, pituitary, and the limbic and neo-cortex. 10, 11 The D 3 receptor subtype is highly localized to the ventral striatum and may functionally oppose D 2 subtype stimulation. 12 The D 4 receptor subtype is distinctive in its predominant distribution to cortex, particularly in the limbic regions, and may have a possible link with cognitive functioning in animals. 13 Which one of these receptors, or groups of receptors, is responsible for antipsychotic activity is still an unanswered question.
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Recently, using an indirect binding technique, increases in the dopamine D 4 receptor density had been reported [1] [2] [3] in schizophrenic subjects but replication of this finding was not always possible. [4] [5] [6] This indirect method consists of subtracting the density found with the D 2 The discovery of NGD-94-1, which is a selective dopamine D 4 receptor antagonist, 7, 8 has provided the opportunity to study D 4 receptor densities in a direct manner. [ 3 H]NGD-94-1 has an affinity for the D 4 receptor which is approximately 1000 times higher than its affinity for the D 2 and D 3 receptors (see also Table 1 ). It also has low affinity at most other monoamine receptors, with its affinity for the cloned 5-HT 1A receptor being the highest. NGD94-1 also has very low affinity for the following receptors such as the muscarinic, sigma, adrenergic, histamine, NMDA, NPY, and opiate receptors. 8 In this study we have used human postmortem tissue from normal subjects and compared them to schizophrenic subjects who were either off antipsychotic drugs for at least 3 months prior to death or schizophrenic subjects on antipsychotic drugs at the time of death. This is important since it is known that chronic antipsychotic drug administration will elevate the number of D 2 -family receptors in the brains of rats. 14, 15 Thus, the use of tissue from drug-free schizophrenic subjects for such a study is essential. Autoradiographic studies obtained through the use of brain sections were employed since they afford the opportunity to study numerous regional brain structures and provide a conservative use of this valuable tissue.
Results of the receptor-binding studies demonstrate the high selectivity of NGD-94-1 for the hD 4 class of receptors, and its low affinity for the hD 2I and hD 3 receptors. Modest affinity of 79 nM was obtained for the cloned h5HT 1A receptor (Table 1 ) and the compound was inactive at the 5HT 2A and 5HT 2C receptors.
An example of both the total and non-specific (3000 nM pimozide) binding obtained with [ 3 H]NGFD-94-1 is presented in Figure 1 . The results obtained with the human tissue are presented in Tables 2 and 3 . The data in Table 2 any region studied, nor between the two patient groups. However, when the two groups of schizophrenic subjects were combined (n = 14), the entorhinal cortex (24.9 vs 36.4, control and schizophrenics, respectively) showed a statistically significantly higher (PϽ0.05) density than those found in brain tissue from controls. No relationships were found between receptor density and either age or postmortem interval.
The data in Table 3 were focused on the hippocampus and medial temporal cortex. The highest levels of binding in controls were in the CA1 region of the hippocampus (42.5 fmol mg −1 ), followed by the outer layers of the collateral sulcus (24.3 and 24.6) and layer III of the entorhinal cortex (17.6). Compared to tissue from normal subjects, increases in the density of binding were observed in the outer layer I-II (11.2 vs 25.9) and layer IV (11.3 vs 29.1) of the entorhinal cortex in the schizophrenic off antipsychotic drug group. In the schizophrenic group on antipsychotic drugs at death, there were increases in binding in the CA1 region of the hippocampus (42.5 vs 74.0), as well as layers I-II (11.2 vs 34.1), IV (11.3 vs 34.0) and V-VI (10.2 vs 27.9) of the entorhinal cortex.
When the data collected at the higher magnification were analyzed with all of the schizophrenic cases together, and compared to controls there were statistically significant increases in binding densities in the CA1 region of the hippocampus (148%) and all layers of the entorhinal cortex (233-280%). There were no significant differences between normals and schizophrenics in any layer of the collateral sulcus. This study demonstrates that in normal human brain tissue, the regions with the highest density of dopamine D 4 ([ 3 H]NGD-94-1) binding were the hippocampus, followed by the collateral sulcus, insula, entorhinal cortex and lesser amounts, in the caudate, putamen and nucleus accumbens. At higher levels of magnification, which permitted more detailed structural analysis, the binding in the CA1 region of the hippocampus was greatest followed by superficial and medial layers of the collateral sulcus and then by layer III of the entorhinal cortex.
These results are similar to the distributions of D 4 receptors estimated using the indirect subtraction method to observe the D 4 receptor distribution in human postmortem tissue. 11 The mRNA for the dopamine D 4 receptor in human postmortem tissue has also been shown to be localized in cortical areas, including the hippocampus, 16 but D 4 mRNA was not found in the caudate, 17 and in another study only relatively low levels of D 4 mRNA were observed in the caudate and substantia nigra. 18 D 4 receptor protein has been reported in the substantia nigra (pars reticulata) of primate brain, 19 however in the caudate-putamen D 4 receptor protein levels were barely above background.
19 D 4 receptor protein has also been shown to be present in rat frontal and parietal cortices with very low levels being found in the rat caudate. 20 Thus, the data presented here on the D 4 receptor distribution are consistent with a majority of other data in which the D 4 receptor was found to be present in the hippocampus and the temporal cortex, with lower amounts being present in the caudate/putamen.
Although the affinity of NGD94 Increases were observed in the density of [ 3 H]NGD-94-1 binding in the entorhinal cortex and substantia nigra of schizophrenic subjects, as a total group, compared to controls. At higher magnification, within the entorhinal cortex, differences in receptor densities were observed between schizophrenic subjects both off and on antipsychotic drugs as compared to normal controls in most of the layers. Differences between normals and schizophrenic subjects on antipsychotic drugs at death were also observed in the CA1 region of the hippocampus at higher magnification. Recently, increases in the mRNA for the D 4 receptor in the frontal cortex of schizophrenic subjects have been reported. 21 No evidence for an increase in the density of the D 4 receptor in the caudate of schizophrenic subjects was found in this study in which the receptor density has been determined by a direct receptor evaluation. Our results are in agreement with other studies on that issue [4] [5] [6] and also with the absence of changes in the D 4 receptor mRNA in schizophrenic subjects compared to normal controls. 21 A reduction in tyrosine hydroxylase (TH) immunoreactivity, an indicator of dopaminergic innervation, in certain layers of the entorhinal cortex has been observed in schizophrenics. 22 Such a reduction in dopamine could lead to an upregulation of dopamine receptors in that region. Moreover, cytochemical abnormalities in the entorhinal cortex of schizophrenic subjects have been noted. [23] [24] [25] These abnormalities include aberrant invaginations of the surface, disruption of cortical layers, heterotopic displacement of neurons, and paucity of neurons in superficial layers. It has been further hypothesized that these abnormalities could contribute to the pathophysiology of schizophrenia especially because of the many other reports of hippocampal-entorhinal cortex pathology in schizophrenia. 23, [26] [27] [28] The finding of increases in dopamine D 4 receptor densities in these areas provides evidence for an additional neurochemical abnormality in schizophrenia and supports speculations on a role of the entorhinal cortex in the pathophysiology of schizophrenia.
Since the increases were observed in schizophrenic subjects off antipsychotic drugs for at least 3 months prior to death, this may suggest that the increases in D 4 receptor may be related to the disease and not to its pharmacological treatment. Interestingly, using the subtraction technique to determine D 4 receptor densities, it has been reported that chronic haloperidol administration to rats causes an increase in the number of D 4 receptors in the striatum, but does not cause changes in the cortex. 15 In contrast, we did not find increases in D 4 receptors in the caudate or putamen of schizophrenic subjects on antipsychotic drugs at the time of death, however increases were found in the entorhinal cortex. Again, this may suggest that the changes observed in D 4 receptor density in certain cortical areas of schizophrenic subjects may be diseaserelated and not due to drug treatment. Additional studies are needed to firmly characterize this binding.
Methods

Postmortem brain tissue and demographics
Postmortem brain tissue was obtained from the Maryland Brain Collection (MBC) of the Maryland Psychiatric Research Center. Next of kin had provided informed consent for the use of this tissue in research. For all cases, a Diagnostic Coordinator completed a demographic form in as much detail as possible which lists age, race, sex, socioeconomic status, cause of death, date and time of death, date and time of brain removal, in addition to toxicological report findings, and DSM(IIIR-IV) diagnosis. The demographics of the cases were determined retrospectively using the clinical chart and family reported data obtained by the Diagnostic Coordinator. For schizophrenic cases, the chart was reviewed independently by two MBC psychiatrists, and a diagnosis was decided. For diagnosis, materials available to the psychiatrist include the medical records, Medical Examiner's Report, summary of the clinical interview, notes from family interviews. After reviewing all materials psychiatrists came to a DSM(III-R or IV) diagnosis. After the review of the medical records or interviews with clinicians who were recently involved in treating the patient, a determination was made by the psychiatrist as to whether a case is considered 'off drug' or 'on drug' at time of death, and for how long, with reference to the record of neuroleptic therapy. The MBC rates cases as being on or off neuroleptic drugs in the 6 months, 3 months or 1 month prior to death. For control cases a similar procedure is used and one MBC psychiatrist reviews the presented chart with all research assessments and reports and assigns a diagnosis.
The demographics of the cases used in this study are presented in Table 4 . There were 13 normal subjects, seven schizophrenic subjects off antipsychotic drugs at least 3 months prior to death and seven schizophrenic subjects on antipsychotic drugs at the time of death. Two of the normal subjects were found to have used cocaine according to the toxicological report, and one of the schizophrenic off drug cases was a cocaine abuser, but that toxicology report was negative for cocaine. For the schizophrenic on drug cases, the anti- psychotic drugs being used were haloperidol, fluphenazine, thioridazine and trifluoperazine. For 10 of the total cases studied, for whom such information was available, the mean age-of-onset was 24.2 ± 4.5 yrs and the mean duration of illness was 24.6 ± 11.1 yrs.
Tissue preparation and autoradiography
Human postmortem coronal brain sections (10 M) from approximately 60 × 40 × 20 mm blocks of tissue collected at the level of the caudate and the hippocampus were used. 3 The tissue sections were thaw mounted onto 75 × 50 mm gelatin-coated subbed slides, air dried, desiccated overnight, then stored at −80°C until used. In the autoradiographic studies three sections from each block and each case were used for total binding and one section from each block and each case was used for non-specific binding. The non-specific binding determinant was 3000 nM pimozide. For the incubations the slides were removed from the freezer, placed in an 8°C cold room for 10 min, into 8°C 50 mM TRIS, pH 7.4, for 15 min, then into 50 mM TRIS containing 10 mM MgCl 2 and 6 nM [ 3 H]NGD-94-1 (sp. act. 44.4 Ci mmol −1 ) for 2 h at 22°C. Sections were then rinsed in cold 50 mM TRIS for 10 s, then for 30 s, and into 22°C deionized water three times for 10 s each. Slides were air dried, desiccated overnight, apposed to [ 3 H]Hyperfilm for 3 months, along with tritium standards. Films were developed using D-19 developer, digitized and regions of interest quantified using a Loats image analyzer (Loats Associates, Westminster, MD, USA). Optical density values were converted to femtomoles mg −1 using the Amersham tritium standards and the appropriate conversion factors. Although the subject classifications were known, quantification of the autoradiograms was done in a random manner and data sorted at the time of final analysis.
Films of the hippocampus were digitized at two different magnification levels. The first setting was with the camera 25 cm above the film in order to digitize the majority of the section. A second digitization was made at a higher magnification with a camera height of 10 cm above the film providing greater structural definition. The entorhinal cortex was quantified approximating layers I-II, III, IV, and V-VI; and for the collateral sulcus, three regions 16 were labeled as the superficial laminae (s), middle layers (m) and deeper layers (d); the CA1 region of the hippocampus was also quantified.
Receptor affinity characterization
Receptor-binding studies to determine NGD-94-1 affinities for the hD 1A , hD 2I , hD 3 , hD 4.2 , hD 4.4 , hD 4.7 , h5HT 1A , r5HT 2A , r5HT 2C (h = human; r = rat) were conducted in this laboratory as previously described. 11 For the 5HT 1A receptor the ligand was [ 3 H]8-hydroxy-DPAT and the membranes were from Chinese hamster ovarian (CHO) cells stably transfected with the h5HT 1A receptor. 29 
Statistical analysis
Receptor density data obtained from controls, schizophrenics off, and schizophrenics on antipsychotic drugs at the time of death, and within a brain region were analyzed using one-way ANOVA and StudentNewman-Kuels post-hoc test (Instat Program, GraphPad) and the results were controlled for multiple comparisons.
